Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit
Co-Diagnostics (NASDAQ:CODX) has been recognized at the Utah Business 2025 Innovation Awards Summit for its Co-Dx PCR platform in the Healthcare and Life Sciences category. The platform, which includes the Co-Dx PCR Home鈩�, Co-Dx PCR Pro鈩�, mobile app, and associated tests and software, was honored for its innovative approach to molecular diagnostics.
CEO Dwight Egan accepted the award, highlighting the company's commitment to expanding access to high-quality PCR diagnostics globally. The platform is currently pending regulatory review by the FDA and other bodies, with commercialization expected in 2026.
Co-Diagnostics (NASDAQ:CODX) 猫 stata premiata agli Utah Business 2025 Innovation Awards Summit nella categoria Healthcare and Life Sciences per la sua piattaforma Co-Dx PCR. La piattaforma, che comprende il Co-Dx PCR Home鈩�, il Co-Dx PCR Pro鈩�, l'app mobile e i relativi test e software, 猫 stata riconosciuta per l'approccio innovativo alla diagnostica molecolare.
Il CEO Dwight Egan ha ritirato il premio, sottolineando l'impegno dell'azienda nell'ampliare l'accesso a diagnostiche PCR di alta qualit脿 a livello globale. La piattaforma 猫 attualmente in attesa di revisione regolatoria da parte della FDA e di altri enti, con commercializzazione prevista per il 2026.
Co-Diagnostics (NASDAQ:CODX) ha sido reconocida en los Utah Business 2025 Innovation Awards Summit en la categor铆a Healthcare and Life Sciences por su plataforma Co-Dx PCR. La plataforma, que incluye Co-Dx PCR Home鈩�, Co-Dx PCR Pro鈩�, la app m贸vil y las pruebas y software asociados, fue premiada por su enfoque innovador en diagn贸stico molecular.
El CEO Dwight Egan acept贸 el galard贸n, destacando el compromiso de la compa帽铆a por ampliar el acceso a diagn贸sticos PCR de alta calidad a nivel mundial. La plataforma est谩 actualmente pendiente de revisi贸n regulatoria por la FDA y otras entidades, y se espera su comercializaci贸n en 2026.
Co-Diagnostics (NASDAQ:CODX)臧� Utah Business 2025 Innovation Awards Summit鞐愳劀 Healthcare and Life Sciences 攵�氍� Co-Dx PCR 頂岆灚韽�鞙茧 靾橃儊頄堨姷雼堧嫟. 鞚� 頂岆灚韽检潃 Co-Dx PCR Home鈩�, Co-Dx PCR Pro鈩�, 氇皵鞚� 鞎� 氚� 甏�霠� 瓴�靷檧 靻岉攧韸胳洦鞏措ゼ 韽暔頃橂┌ 攵勳瀽 歆勲嫧鞐� 雽�頃� 順侅嫚鞝侅澑 鞝戧芳鞙茧 鞚胳爼氚涭晿鞀惦媹雼�.
CEO 霌滌檧鞚错姼 鞚搓贝(Dwight Egan)鞚� 靸侅潉 靾橃儊頃橂┌ 鞝� 靹戈硠鞝侅溂搿� 瓿犿拡歆� PCR 歆勲嫧 鞝戧芳靹膘潉 頇曤寑頃橂牑電� 須岇偓鞚� 鞚橃毳� 臧曥“頄堨姷雼堧嫟. 鞚� 頂岆灚韽检潃 順勳灛 FDA 氚� 旮绊儉 旮瓣磤鞚� 攴滌牅 鞁偓毳� 旮半嫟毽碃 鞛堨溂氅�, 靸侅毄頇旊姅 2026雲勳溂搿� 鞓堨儊霅╇媹雼�.
Co-Diagnostics (NASDAQ:CODX) a 茅t茅 reconnue lors du Utah Business 2025 Innovation Awards Summit dans la cat茅gorie Healthcare and Life Sciences pour sa plateforme Co-Dx PCR. La plateforme, qui comprend le Co-Dx PCR Home鈩�, le Co-Dx PCR Pro鈩�, l'application mobile ainsi que les tests et logiciels associ茅s, a 茅t茅 honor茅e pour son approche innovante en diagnostic mol茅culaire.
Le PDG Dwight Egan a accept茅 le prix, mettant en avant l'engagement de la soci茅t茅 脿 茅largir l'acc猫s 脿 des diagnostics PCR de haute qualit茅 脿 l'茅chelle mondiale. La plateforme est actuellement en attente d'examen r茅glementaire par la FDA et d'autres organismes, sa commercialisation 茅tant pr茅vue en 2026.
Co-Diagnostics (NASDAQ:CODX) wurde beim Utah Business 2025 Innovation Awards Summit in der Kategorie Healthcare and Life Sciences f眉r seine Co-Dx PCR-Plattform ausgezeichnet. Die Plattform, zu der Co-Dx PCR Home鈩�, Co-Dx PCR Pro鈩�, eine mobile App sowie dazugeh枚rige Tests und Software geh枚ren, wurde f眉r ihren innovativen Ansatz in der molekularen Diagnostik geehrt.
CEO Dwight Egan nahm die Auszeichnung entgegen und hob das Engagement des Unternehmens hervor, den Zugang zu hochwertigen PCR-Diagnostika weltweit zu erweitern. Die Plattform befindet sich derzeit in beh枚rdlicher Pr眉fung durch die FDA und andere Stellen, eine Kommerzialisierung wird f眉r 2026 erwartet.
- None.
- None.
Utah Business, a publication highlighting the ideas, innovations and people behind
Dwight Egan, Co-Diagnostics CEO, accepted the award on behalf of the Company.
"We are honored that the innovation and future impact of the Co-Dx PCR platform has been recognized by this panel of experts, and would like to thank Utah Business for their efforts in organizing the event," said Mr. Egan. "We look forward to commercialization of the platform next year and to help close the access gap to high-quality PCR diagnostics for patients around the world."
*The Co-Dx PCR platform (including the Co-Dx PCR Home鈩�, Co-Dx PCR Pro鈩�, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
View original content to download multimedia:
SOURCE Co-Diagnostics
FAQ
What award did Co-Diagnostics (CODX) receive in 2025?
When will the Co-Dx PCR platform be available for commercial use?
What products are included in Co-Diagnostics' PCR platform?
Is Co-Diagnostics' PCR platform FDA approved?
